Search results
Results from the WOW.Com Content Network
Celera Corporation is a subsidiary of Quest Diagnostics which focuses on genetic sequencing and related technologies. It was founded in 1998 as a business unit of Applera , spun off into an independent company in 2008, and finally acquired by Quest Diagnostics in 2011.
These two groups were the S&P 500 listed Applera Corp-Applied Biosystems Group of Foster City, California, and Applera Corp-Celera Genomics Group of Rockville, Maryland. In 2006, the company spun off the Celera Genomics group and changed its name from Applera to Applied Biosystems. As the former Perkin-Elmer, Applera had a history dating back ...
[3] [4] Venter founded Celera Genomics, the Institute for Genomic Research (TIGR) and the J. Craig Venter Institute (JCVI). He was the co-founder of Human Longevity Inc. and Synthetic Genomics . He was listed on Time magazine's 2007 and 2008 Time 100 list of the most influential people in the world.
On May 6, 1999, the recapitalization of the company resulted in issuance of the two new classes of common stock, called PE Corporation-PE Biosystems Group Common Stock and PE Corporation-Celera Genomics Group Common Stock. [19] On that date, trading began in both new stocks on the New York Stock Exchange, to great excitement. [18]
A parallel project was conducted outside the government by the Celera Corporation, or Celera Genomics, which was formally launched in 1998. Most of the government-sponsored sequencing was performed in twenty universities and research centres in the United States, the United Kingdom, Japan, France, Germany, and China, [ 7 ] working in the ...
PerkinElmer, Inc., previously styled Perkin-Elmer, is an American global corporation that was founded in 1937 and originally focused on precision optics.Over the years it went into and out of several different businesses via acquisitions and divestitures; these included defense products, semiconductors, computer systems, and others.
Venter (and Smith)'s previous company, Celera Genomics, was a driving force in the race to sequence the human genome. [9] The firm takes its name from the phrase synthetic genomics which is a scientific discipline of synthetic biology related to the generation of organisms artificially using genetic material. [10] [11]
After leaving the NCI, Dr. Broder became Senior Vice President for Research and Development at the IVAX Corporation in Florida, a position he held until 1998 when he joined Celera Genomics. He is now Chief Medical Officer of Celera. He has received a number of honors for his work including the Arthur S. Flemming Award and the Leopold Griffuel ...